Free Trial
NASDAQ:CTKB

Cytek Biosciences (CTKB) Stock Price, News & Analysis

Cytek Biosciences logo
$3.48 +0.08 (+2.35%)
Closing price 07/1/2025 04:00 PM Eastern
Extended Trading
$3.48 +0.00 (+0.14%)
As of 07/1/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cytek Biosciences Stock (NASDAQ:CTKB)

Key Stats

Today's Range
$3.38
$3.60
50-Day Range
$2.42
$3.86
52-Week Range
$2.37
$7.63
Volume
1.13 million shs
Average Volume
819,132 shs
Market Capitalization
$440.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.60
Consensus Rating
Hold

Company Overview

Cytek Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

CTKB MarketRank™: 

Cytek Biosciences scored higher than 63% of companies evaluated by MarketBeat, and ranked 442nd out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cytek Biosciences has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Cytek Biosciences has only been the subject of 3 research reports in the past 90 days.

  • Read more about Cytek Biosciences' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cytek Biosciences is -38.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cytek Biosciences is -38.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cytek Biosciences has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Cytek Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    4.44% of the float of Cytek Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytek Biosciences has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Cytek Biosciences has recently decreased by 5.91%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cytek Biosciences does not currently pay a dividend.

  • Dividend Growth

    Cytek Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.44% of the float of Cytek Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytek Biosciences has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Cytek Biosciences has recently decreased by 5.91%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cytek Biosciences has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Cytek Biosciences this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for CTKB on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cytek Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $194,600.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    10.33% of the stock of Cytek Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cytek Biosciences' insider trading history.
Receive CTKB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CTKB Stock News Headlines

Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
See More Headlines

CTKB Stock Analysis - Frequently Asked Questions

Cytek Biosciences' stock was trading at $6.49 on January 1st, 2025. Since then, CTKB stock has decreased by 46.4% and is now trading at $3.48.
View the best growth stocks for 2025 here
.

Cytek Biosciences, Inc. (NASDAQ:CTKB) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.05. The firm had revenue of $41.46 million for the quarter, compared to the consensus estimate of $43.18 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 2.90% and a negative net margin of 5.71%.
Read the conference call transcript
.

Cytek Biosciences' Board of Directors approved a stock buyback plan on Monday, December 30th 2024, which allows the company to repurchase $50,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 5.9% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's board believes its shares are undervalued.

Cytek Biosciences (CTKB) raised $248 million in an initial public offering (IPO) on Friday, July 23rd 2021. The company issued 14,564,635 shares at $16.00-$18.00 per share.

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytek Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AU Optronics (AUOTY) and Humana (HUM).

Company Calendar

Last Earnings
5/08/2025
Today
7/01/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:CTKB
Fax
N/A
Employees
500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.60
High Stock Price Target
$8.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+60.9%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$6.02 million
Pretax Margin
-4.05%

Debt

Sales & Book Value

Annual Sales
$200.45 million
Cash Flow
$0.03 per share
Price / Cash Flow
102.30
Book Value
$3.07 per share
Price / Book
1.13

Miscellaneous

Free Float
113,575,000
Market Cap
$440.78 million
Optionable
Optionable
Beta
1.26
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:CTKB) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners